Genomma Lab Internacional, S.A.B. de C.V. Stock price

Equities

LAB B

MX01LA010006

Pharmaceuticals

End-of-day quote Mexican S.E. 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
15.78 MXN +1.61% Intraday chart for Genomma Lab Internacional, S.A.B. de C.V. +5.98% +11.44%
Sales 2023 16.47B 993M Sales 2024 * 18.09B 1.09B Capitalization 14.67B 884M
Net income 2023 1.03B 62.15M Net income 2024 * 2.3B 139M EV / Sales 2023 1.07 x
Net Debt 2023 4.52B 272M Net Debt 2024 * 1.97B 119M EV / Sales 2024 * 0.9 x
P/E ratio 2023
13.1 x
P/E ratio 2024 *
7.17 x
Employees 1,783
Yield 2023
1.38%
Yield 2024 *
0.98%
Free-Float 69.81%
More Fundamentals * Assessed data
Dynamic Chart
Genomma Lab Internacional, S.A.B. De C.V. Declares Cash Dividend CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q4 2023 Earnings Call, Feb 22, 2024
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Genomma Lab Internacional, S.A.B. De C.V. Announces Sixth Dividend Payment CI
Procaps Group and Genomma Lab Announce Strategic Agreement to Manufacture and Market Softgel Products in Latin America CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q3 2023 Earnings Call, Oct 26, 2023
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q2 2023 Earnings Call, Jul 27, 2023
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q1 2023 Earnings Call, Apr 27, 2023
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V. - Analyst/Investor Day
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q4 2022 Earnings Call, Feb 23, 2023
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
More news

Latest transcript on Genomma Lab Internacional, S.A.B. de C.V.

1 day+1.61%
1 week+5.98%
Current month+19.91%
1 month+13.28%
3 months+9.43%
6 months+13.36%
Current year+11.44%
More quotes
1 week
14.71
Extreme 14.71
15.93
1 month
13.03
Extreme 13.03
15.93
Current year
12.39
Extreme 12.39
15.93
1 year
12.39
Extreme 12.39
15.93
3 years
12.39
Extreme 12.39
23.00
5 years
12.39
Extreme 12.39
24.58
10 years
8.75
Extreme 8.75
37.15
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Founder - 96-10-29
Director of Finance/CFO - -
Members of the board TitleAgeSince
Director/Board Member 70 18-04-17
Founder - 96-10-29
Director/Board Member - 97-12-31
More insiders
Date Price Change Volume
24-03-27 15.78 +1.61% 2,956,863
24-03-26 15.53 +0.45% 2,370,549
24-03-25 15.46 +2.45% 4,433,692
24-03-22 15.09 -1.11% 2,253,847
24-03-21 15.26 +2.48% 2,608,205

End-of-day quote Mexican S.E., March 26, 2024

More quotes
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company's product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
15.78 MXN
Average target price
21.11 MXN
Spread / Average Target
+33.80%
Consensus
  1. Stock
  2. Equities
  3. Stock Genomma Lab Internacional, S.A.B. de C.V. - Mexican S.E.